跳至主要内容
临床试验/IRCT138904241475N5
IRCT138904241475N5已完成3 期

Double blind, randomized clinical trial on efficacy of combination of meglumine antimoniate (Glucantime) and topical nano-liposomal paromomycin for the treatment of anthroponotic cutaneous leishmaniasis (ACL) caused by Leishmania tropica

The Eastern Mediterranean Regional Office (EMRO) of the World Health Organization (WHO)0 个研究点目标入组 120 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
12 years 至 60 years(—)
性别
All

入选标准

  • I) a) Parasitologically proven cases* of CL based on positive smear and/or culture; b) Otherwise healthy subjects on the basis of medical history, physical examination and results of blood test (if seemed necessary by the physician); c) Age 12-60 years; d) Willing to participate in the study and sign the informed consent (by the patient or his/her parent/guardian in case of younger than 18 years).
  • * Direct smear, culture and PCR will be done on every sample to identify the causative agent.
  • II) Exclusion criteria: a) Pregnant or lactating women; b) Duration of lesion more than 6 months; c) Number of lesions more than 4; d) Ulcer size greater than 3 cm in their largest diameter; e) History of full course of standard treatment (antimonials); f) History of allergy to Glucantime; g) Serious systemic illnesses (as judged by the physician); h) Participation in any drug trials in the last 60 days.

排除标准

  • 未提供

研究者

发起方
The Eastern Mediterranean Regional Office (EMRO) of the World Health Organization (WHO)

相似试验